Botulinum toxin in the treatment of orofacial tardive dyskinesias: a single blind study.
Completed
- Conditions
- /A
- Registration Number
- NL-OMON24924
- Lead Sponsor
- Botulinum toxin A ampules by Ipsen, pharmaceutical group
- Brief Summary
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):507-9. Epub 2007 Oct 13.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 14
Inclusion Criteria
Patients suffering from orofacial tardive dyskinisias for at least 3 months, stable dosage of psychopharmacological medication and written informed consent by the patient.
Exclusion Criteria
Age younger than 18 years, contraindication for botulinum toxin (myasthenia gravis, Lambert Eaton Myasthenic Syndrome) and women known to be pregnant or having a positive pregnancy test.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method